Search Results - "HSU, Yanzhi"

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial by Fuchs, Charles S, Dr Prof, Tomasek, Jiri, MD, Yong, Cho Jae, Prof, Dumitru, Filip, MD, Passalacqua, Rodolfo, MD, Goswami, Chanchal, Prof, Safran, Howard, Prof, dos Santos, Lucas Vieira, MD, Aprile, Giuseppe, MD, Ferry, David R, Prof, Melichar, Bohuslav, Prof, Tehfe, Mustapha, MD, Topuzov, Eldar, Prof, Zalcberg, John Raymond, Prof, Chau, Ian, MD, Campbell, William, Prof, Sivanandan, Choondal, MD, Pikiel, Joanna, MD, Koshiji, Minori, MD, Hsu, Yanzhi, PhD, Liepa, Astra M, PharmD, Gao, Ling, PhD, Schwartz, Jonathan D, MD, Tabernero, Josep, MD

“…Summary Background Vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the…”
Get full text

Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab by Zhu, Andrew X., Finn, Richard S., Kang, Yoon-Koo, Yen, Chia-Jui, Galle, Peter R., Llovet, Josep M., Assenat, Eric, Brandi, Giovanni, Motomura, Kenta, Ohno, Izumi, Daniele, Bruno, Vogel, Arndt, Yamashita, Tatsuya, Hsu, Chih-Hung, Gerken, Guido, Bilbruck, John, Hsu, Yanzhi, Liang, Kun, Widau, Ryan C., Wang, Chunxiao, Abada, Paolo, Kudo, Masatoshi

“…Background Post hoc analyses assessed the prognostic and predictive value of baseline alpha-fetoprotein (AFP), as well as clinical outcomes by AFP response or…”
Get full text

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer by Tabernero, Josep, Ohtsu, Atsushi, Muro, Kei, Van Cutsem, Eric, Oh, Sang Cheul, Bodoky, György, Shimada, Yasuhiro, Hironaka, Shuichi, Ajani, Jaffer A, Tomasek, Jiri, Safran, Howard, Chandrawansa, Kumari, Hsu, Yanzhi, Heathman, Michael, Khan, Azhar, Ni, Lan, Melemed, Allen S, Gao, Ling, Ferry, David, Fuchs, Charles S

“…Ramucirumab is an IgG monoclonal antibody specific for the vascular endothelial growth factor receptor-2. Ramucirumab, 8 mg/kg every 2 weeks, administered as…”
Get full text

Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial by Yoshino, Takayuki, Obermannová, Radka, Bodoky, György, Garcia-Carbonero, Rocio, Ciuleanu, Tudor, Portnoy, David C, Kim, Tae Won, Hsu, Yanzhi, Ferry, David, Nasroulah, Federico, Tabernero, Josep

“…Abstract Background The RAISE phase III clinical trial demonstrated that ramucirumab + (folinic acid plus 5-fluorouracil plus irinotecan) FOLFIRI significantly…”
Get full text

Exposure–response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer by Kim, Tae You, Yen, Chia-Jui, Al-Batran, Salah-Eddin, Ferry, David, Gao, Ling, Hsu, Yanzhi, Cheng, Rebecca, Orlando, Mauro, Ohtsu, Atsushi

“…Background Ramucirumab is a recombinant human IgG1 neutralizing monoclonal antibody specific for vascular endothelial growth factor receptor-2. Second-line…”
Get full text

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data by Fuchs, Charles S, Muro, Kei, Tomasek, Jiri, Van Cutsem, Eric, Cho, Jae Yong, Oh, Sang-Cheul, Safran, Howard, Bodoky, György, Chau, Ian, Shimada, Yasuhiro, Al-Batran, Salah-Eddin, Passalacqua, Rodolfo, Ohtsu, Atsushi, Emig, Michael, Ferry, David, Chandrawansa, Kumari, Hsu, Yanzhi, Sashegyi, Andreas, Liepa, Astra M, Wilke, Hansjochen

“…To identify baseline prognostic factors for survival in patients with disease progression, during or after chemotherapy for the treatment of advanced gastric…”
Get full text

Exploratory analysis of left- versus right-sided colorectal carcinoma in RAISE: A randomized, double-blind, phase 3 trial of ramucirumab (RAM) + FOLFIRI versus placebo (PBO) + FOLFIRI by Portnoy, David Craig, Obermannova, Radka, Bodoky, Gyorgy, Prausová, Jana, Garcia-Carbonero, Rocio, Ciuleanu, Tudor-Eliade, Garcia Alfonso, Pilar, Cohn, Allen Lee, Van Cutsem, Eric, Yamazaki, Kentaro, Yoshino, Takayuki, Lonardi, Sara, Kim, Tae Won, Yamaguchi, Kensei, Grothey, Axel, O Connor, Juan Manuel, Hsu, Yanzhi, Ferry, David, Nasroulah, Federico, Tabernero, Josep

“…Abstract only 668 Background: Ramucirumab is a human IgG1 monoclonal antibody antagonist of VEGFR-2. Overall survival (OS) and progression-free survival (PFS)…”
Get full text

Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies by Yen, Chia-Jui, Kudo, Masatoshi, Lim, Ho-Yeong, Hsu, Chih-Hung, Vogel, Arndt, Brandi, Giovanni, Cheng, Rebecca, Nitu, Ioana Simona, Abada, Paolo, Hsu, Yanzhi, Zhu, Andrew X., Kang, Yoon-Koo

“…Objective: REACH-2 and REACH were randomized, placebo-controlled, double-blind, multicenter phase 3 trials which showed survival benefits of ramucirumab…”
Get full text

DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population by Chen, Senqing, Tang, Deliang, Xue, Kaixian, Xu, Lin, Ma, Guojian, Hsu, Yanzhi, Cho, Stanley S.

“…X-ray repair cross-complementing group 1 (XRCC1) and xeroderma pigmentosum group D (XPD) are mainly involved in base excision repair (BER) and nucleotide…”
Get full text

In Utero DNA Damage from Environmental Pollution Is Associated with Somatic Gene Mutation in Newborns by PERERA, Frederica, HEMMINKI, Karl, JEDRYCHOWSKI, Wieslaw, WHYATT, Robin, CAMPBELL, Ulka, HSU, Yanzhi, SANTELLA, Regina, ALBERTINI, Richard, O'NEILL, James P

“…Transplacental exposure to carcinogenic air pollutants from the combustion of fossil fuels is a growing health concern, given evidence of the heightened…”
Get full text

Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer by DELIANG TANG, STAN CHO, RUNDLE, Andrew, SENQING CHEN, PHILLIPS, David, JINGZHI ZHOU, YANZHI HSU, SCHNABEL, Freya, ESTABROOK, Alison, PERERA, Frederica P

“…We present findings on the associations between DNA adduct levels in breast tissue, risk of breast cancer, and polymorphisms in the DNA repair enzyme XPD…”
Get full text

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial by Zhu, Andrew X, Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S, Galle, Peter R, Llovet, Josep M, Assenat, Eric, Brandi, Giovanni, Pracht, Marc, Lim, Ho Yeong, Rau, Kun-Ming, Motomura, Kenta, Ohno, Izumi, Merle, Philippe, Daniele, Bruno, Shin, Dong Bok, Gerken, Guido, Borg, Christophe, Hiriart, Jean-Baptiste, Okusaka, Takuji, Morimoto, Manabu, Hsu, Yanzhi, Abada, Paolo B, Kudo, Masatoshi

“…Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of…”
Get full text

Gender Differences in Autoantibodies to Oxidative DNA Base Damage in Cigarette Smokers by Mooney, L A, Perera, F P, Van Bennekum, A M, Blaner, W S, Karkoszka, J, Covey, L, Hsu, Y, Cooper, T B, Frenkel, K

“…Oxidative DNA damage and antibodies to that damage have been implicated in lung, breast, and colorectal cancer. In this observational validation study, the…”
Get full text

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data by Fuchs, Charles S, Muro, Kei, Tomasek, Jiri, Van Cutsem, Eric, Cho, Jae Yong, Oh, Sang-Cheul, Safran, Howard, Bodoky, Gyorgy, Chau, Ian, Shimada, Yasuhiro, Al-Batran, Salah-Eddin, Passalacqua, Rodolfo, Ohtsu, Atsushi, Emig, Michael, Ferry, David, Chandrawansa, Kumari, Hsu, Yanzhi, Sashegyi, Andreas, Liepa, Astra M, Wilke, Hansjochen

“…Purpose: To identify baseline prognostic factors for survival in patients with disease progression, during or after chemotherapy for the treatment of advanced…”
Get full text

Response to Letter to the Editor, ‘Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,’ by Ibrahim et al by Yoshino, Takayuki, Hsu, Yanzhi, Nasroulah, Federico

Get full text

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis by Steinman, Lawrence, Fox, Edward, Hartung, Hans-Peter, Alvarez, Enrique, Qian, Peiqing, Wray, Sibyl, Robertson, Derrick, Huang, DeRen, Selmaj, Krzysztof, Wynn, Daniel, Cutter, Gary, Mok, Koby, Hsu, Yanzhi, Xu, Yihuan, Weiss, Michael S., Bosco, Jenna A., Power, Sean A., Lee, Lily, Miskin, Hari P., Cree, Bruce A.C.

“…In two parallel randomized trials in patients with MS, ublituximab resulted in lower relapse rates and fewer brain lesions on MRI than teriflunomide over a…”
Get full text

Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials by Chau, Ian, Fuchs, Charles S., Ohtsu, Atsushi, Barzi, Afsaneh, Liepa, Astra M., Cui, Zhanglin Lin, Hsu, Yanzhi, Al-Batran, Salah-Eddin

“…Inadequate understanding of interpretation of quality of life (QoL) instruments leads to unsatisfactory data reporting and clinical decision-making, including…”
Get full text

Meaningful changes in quality of life (QoL) in patients with gastric cancer: Exploratory analyses from RAINBOW and REGARD by Chau, Ian, Fuchs, Charles S., Ohtsu, Atsushi, Liepa, Astra M., Cui, Zhanglin Lin, Hsu, Yanzhi, Al-Batran, Salah-Eddin

“…Abstract only 4047 Background: EORTC QLQ-C30 is a well-established QoL instrument for cancer patients (pts), but there is limited information for gastric…”
Get full text

Associations of quality of life (QoL) with adverse events and tumor response in patients with advanced gastric cancer: Exploratory analyses from RAINBOW and REGARD by Chau, Ian, Fuchs, Charles, Ohtsu, Atsushi, Liepa, Astra, Cui, Zhanglin, Hsu, Yanzhi, Al-Batran, Salah-Eddin

Get full text

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study by Chau, Ian, Park, Joon Oh, Ryoo, Baek-Yeol, Yen, Chia-Jui, Poon, Ronnie, Pastorelli, Davide, Blanc, Jean-Frédéric, Kudo, Masatoshi, Pfiffer, Tulio, Hatano, Etsuro, Chung, Hyun Cheol, Kopeckova, Katerina, Phelip, Jean-Marc, Brandi, Giovanni, Ohkawa, Shinichi, Li, Chung-Pin, Okusaka, Takuji, Hsu, Yanzhi, Abada, Paolo B., Zhu, Andrew X.

“…Background Post-hoc analyses of AFP response and progression and their relationship with objective measures of response and survival were performed in patients…”
Get full text